Boston Scientific recently announced a significant reduction in its expected tariff charges for the year, down to $100 million from the initial forecast of $200 million. This move comes in response to a trend across the medtech industry, where companies are revising their financial outlooks due to additional costs incurred from tariffs imposed by the Trump administration.
Johnson & Johnson and Abbott have also adjusted their projections, highlighting the widespread impact of these policies. The company anticipates the majority of the $100 million impact to be felt in the second half of the year, signaling potential challenges ahead. Despite this, Boston Scientific remains optimistic, raising its full-year sales guidance to reflect a sales growth range of 18% to 19%. The company’s success in the electrophysiology sector, particularly with pulsed field ablation devices, continues to drive its performance and portfolio expansion.
Read more from medtechdive.com